Literature DB >> 15890902

Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2.

Darya Zharikova1, Krystyna Mozdzanowska, Jingqi Feng, Manxin Zhang, Walter Gerhard.   

Abstract

The ectodomain of matrix protein 2 (M2e) of human influenza type A virus strains has remained remarkably conserved since 1918. Because M2e-specific immunity has been shown to decrease morbidity and mortality associated with influenza virus infection in several animal models and because natural infection and current vaccines do not appear to induce a good M2e-specific antibody (Ab) response, M2e has been considered as potential vaccine for inducing cross-reactive protection against influenza type A viruses. The high degree of structural conservation of M2e could in part be the consequence of a poor M2e-specific Ab response and thus the absence of pressure for change. To assess this possibility, we studied the course of infection in SCID mice in the presence or absence of passive M2e-specific monoclonal Abs (MAbs). We found that virus mutants with antigenic changes in M2e emerged in 65% of virus-infected mice treated with M2e-specific but not control MAbs. However, the diversity of escape mutants was highly restricted since only two types were isolated from 22 mice, one with a proline-to-leucine and the other with a proline-to-histidine interchange at amino acid position 10 of M2e. The implications of these findings for the use of M2e as a broadly protective vaccine are discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15890902      PMCID: PMC1112148          DOI: 10.1128/JVI.79.11.6644-6654.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype.

Authors:  Jing Qi Feng; Krystyna Mozdzanowska; Walter Gerhard
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

2.  A universal influenza A vaccine based on the extracellular domain of the M2 protein.

Authors:  S Neirynck; T Deroo; X Saelens; P Vanlandschoot; W M Jou; W Fiers
Journal:  Nat Med       Date:  1999-10       Impact factor: 53.440

3.  Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus.

Authors:  Paul P Heinen; Frans A Rijsewijk; Els A de Boer-Luijtze; André T J Bianchi
Journal:  J Gen Virol       Date:  2002-08       Impact factor: 3.891

4.  Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity.

Authors:  Andrea Jegerlehner; Nicole Schmitz; Tazio Storni; Martin F Bachmann
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

5.  Influenza virus hemagglutinin concentrates in lipid raft microdomains for efficient viral fusion.

Authors:  Makoto Takeda; George P Leser; Charles J Russell; Robert A Lamb
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-15       Impact factor: 11.205

6.  Virus-neutralizing activity mediated by the Fab fragment of a hemagglutinin-specific antibody is sufficient for the resolution of influenza virus infection in SCID mice.

Authors:  Krystyna Mozdzanowska; Jingqi Feng; Walter Gerhard
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

7.  Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2.

Authors:  Krystyna Mozdzanowska; JinQi Feng; Mark Eid; Goran Kragol; Mare Cudic; Laszlo Otvos; Walter Gerhard
Journal:  Vaccine       Date:  2003-06-02       Impact factor: 3.641

8.  Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge.

Authors:  Wanli Liu; Peng Zou; Ying-Hua Chen
Journal:  Immunol Lett       Date:  2004-05-15       Impact factor: 3.685

9.  Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys.

Authors:  Jiang Fan; Xiaoping Liang; Melanie S Horton; Helen C Perry; Michael P Citron; Gwen J Heidecker; Tong-Ming Fu; Joseph Joyce; Craig T Przysiecki; Paul M Keller; Victor M Garsky; Roxana Ionescu; Yvette Rippeon; Li Shi; Michael A Chastain; Jon H Condra; Mary-Ellen Davies; Jason Liao; Emilio A Emini; John W Shiver
Journal:  Vaccine       Date:  2004-08-13       Impact factor: 3.641

10.  N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication.

Authors:  Wanli Liu; Hua Li; Ying-Hua Chen
Journal:  FEMS Immunol Med Microbiol       Date:  2003-03-20
View more
  53 in total

1.  A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge.

Authors:  Dongming Zhou; Te-Lang Wu; Marcio O Lasaro; Brian P Latimer; Elizabeth M Parzych; Ang Bian; Yan Li; Hua Li; Jan Erikson; Zhiquan Xiang; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2010-09-28       Impact factor: 11.454

2.  Detection of site-specific positive Darwinian selection on pandemic influenza A/H1N1 virus genome: integrative approaches.

Authors:  Ramaiah Arunachalam
Journal:  Genetica       Date:  2013-03-26       Impact factor: 1.082

Review 3.  Measles, the need for a paradigm shift.

Authors:  Emilie Javelle; Philippe Colson; Philippe Parola; Didier Raoult
Journal:  Eur J Epidemiol       Date:  2019-10-17       Impact factor: 8.082

4.  Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses.

Authors:  Andres G Grandea; Ole A Olsen; Thomas C Cox; Mark Renshaw; Philip W Hammond; Po-Ying Chan-Hui; Jennifer L Mitcham; Witold Cieplak; Shaun M Stewart; Michael L Grantham; Andrew Pekosz; Maki Kiso; Kyoko Shinya; Masato Hatta; Yoshihiro Kawaoka; Matthew Moyle
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-01       Impact factor: 11.205

5.  Fc receptor is not required for inducing antibodies but plays a critical role in conferring protection after influenza M2 vaccination.

Authors:  Yu-Na Lee; Young-Tae Lee; Min-Chul Kim; Hye Suk Hwang; Jong Seok Lee; Ki-Hye Kim; Sang-Moo Kang
Journal:  Immunology       Date:  2014-10       Impact factor: 7.397

Review 6.  Heterosubtypic immunity to influenza A virus: where do we stand?

Authors:  Kristie M Grebe; Jonathan W Yewdell; Jack R Bennink
Journal:  Microbes Infect       Date:  2008-07-09       Impact factor: 2.700

7.  Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses.

Authors:  Graeme E Price; Mark R Soboleski; Chia-Yun Lo; Julia A Misplon; Mary R Quirion; Katherine V Houser; Melissa B Pearce; Claudia Pappas; Terrence M Tumpey; Suzanne L Epstein
Journal:  PLoS One       Date:  2010-10-04       Impact factor: 3.240

8.  Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1.

Authors:  Stephen Mark Tompkins; Zi-Shan Zhao; Chia-Yun Lo; Julia A Misplon; Teresa Liu; Zhiping Ye; Robert J Hogan; Zhengqi Wu; Kimberly A Benton; Terrence M Tumpey; Suzanne L Epstein
Journal:  Emerg Infect Dis       Date:  2007-03       Impact factor: 6.883

9.  Cross-reactive Antibodies against avian influenza virus A (H5N1).

Authors:  Sathit Pichyangkul; Anan Jongkaewwattana; Arunee Thitithanyanont; Peeraya Ekchariyawat; Suwimon Wiboon-ut; Amporn Limsalakpetch; Kosol Yongvanitchit; Utaiwan Kum-Arb; Rangsini Mahanonda; Pongsak Utaisincharoen; Stitaya Sirisinha; Carl J Mason; Mark M Fukuda
Journal:  Emerg Infect Dis       Date:  2009-09       Impact factor: 6.883

Review 10.  Monoclonal antibody-based therapies for microbial diseases.

Authors:  Carolyn Saylor; Ekaterina Dadachova; Arturo Casadevall
Journal:  Vaccine       Date:  2009-12-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.